Wang Peipei, Chen Yueyun, Wang Chun
Department of Biotherapy, Cancer Center, West China Hospital, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, China.
Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China.
Front Oncol. 2021 Apr 29;11:672677. doi: 10.3389/fonc.2021.672677. eCollection 2021.
Immunotherapy has significantly improved the clinical outcome of patients with cancer. However, the immune response rate varies greatly, possibly due to lack of effective biomarkers that can be used to distinguish responders from non-responders. Recently, clinical studies have associated high tumor neoantigen burden (TNB) with improved outcomes in patients treated with immunotherapy. Therefore, TNB has emerged as a biomarker for immunotherapy and other types of therapy. In the present review, the potential application of TNB as a biomarker was evaluated. The methods of neoantigen prediction were summarized and the mechanisms involved in TNB were investigated. The impact of high TNB and increased number of infiltrating immune cells on the efficacy of immunotherapy was also addressed. Finally, the future challenges of TNB were discussed.
免疫疗法显著改善了癌症患者的临床疗效。然而，免疫反应率差异很大，这可能是由于缺乏可用于区分应答者和非应答者的有效生物标志物。最近，临床研究表明，肿瘤新抗原负荷（TNB）高与接受免疫疗法治疗的患者预后改善相关。因此，TNB已成为免疫疗法和其他类型疗法的生物标志物。在本综述中，评估了TNB作为生物标志物的潜在应用。总结了新抗原预测方法，并研究了TNB涉及的机制。还探讨了高TNB和浸润免疫细胞数量增加对免疫疗法疗效的影响。最后，讨论了TNB未来面临的挑战。
